Dr. Wenfeng Fang 方文峰
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and targeted therapy for lung cancer, nasopharyngeal carcinoma, and other solid tumors. Leads clinical trials for new anti-tumor drugs, including PD-1 monoclonal antibodies and small-molecule targeted agents.
Dr. Fang is a Chief Physician and doctoral supervisor at Sun Yat-sen University Cancer Center. Trained at Wuhan University (MD/PhD) with research experience at the University of Illinois at Chicago and UCLA. Completed residency and fellowship at Sun Yat-sen University Cancer Center. Research focuses on drug resistance mechanisms in lung and colorectal cancers.
Name order: in Chinese the family name comes first (Fang Wenfeng). Papers usually list the name as Wenfeng Fang or Fang W.
Selected publications
288 papers on PubMed matched by name and affiliation; 41 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell, 2026 (senior author): Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. PubMed 42314664
- JAMA Oncol, 2026 (senior author): First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial. PubMed 41746630
- J Clin Invest, 2026 (senior author): EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ. PubMed 41538362
- iScience, 2026 (senior author): Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study. PubMed 41660271
- N Engl J Med, 2026 (first author): Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. PubMed 41124220
- Cancer Med, 2025 (first author): Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial. PubMed 41388935
- Nat Med, 2025 (senior author): First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. PubMed 40830660
- J Hematol Oncol, 2025 (senior author): Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study. PubMed 40713827
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion